Background Although new molecular diagnostic tests such as GenoType MTBDR plus and
Xpert® MTB/RIF have reduced multidrug-resistant tuberculosis (MDR-TB) treatment initiation …

Tuberculosis (TB) is one of the leading causes of death globally from a single infectious
agent, despite being a preventable and curable disease. 1 A significant concern is the large …

Background. Resistance to commonly used antituberculosis drugs is emerging worldwide.
Conventional drug-susceptibility testing (DST) methods are slow and demanding …

Globally, tuberculosis (TB) is a problem of staggering proportions. Between 8 and 9 million
people develop TB disease, and approximately 2 million die as a consequence every year …

Reliable and relevant research can help to improve tuberculosis control worldwide. In recent
years, various organisations have assessed research needs and proposed priorities for …

Background Genotypic (molecular) methods have considerable advantages for scaling up
programmatic management and surveillance of drug-resistant tuberculosis (TB), offering …

Under the terms of this licence, you may copy, redistribute and adapt the work for non-
commercial purposes, provided the work is appropriately cited, as indicated below. In any …

Background Accurate and rapid tests for tuberculosis (TB) drug resistance are critical for
improving patient care and decreasing the transmission of drug‐resistant TB. Genotype® …

Background Global roll-out of rapid molecular assays is revolutionising the diagnosis of
rifampicin resistance, predictive of multidrug-resistance, in tuberculosis. However, 30% of …

Background The World Health Organization (WHO) recommends Xpert MTB/RIF in place of
smear microscopy to diagnose tuberculosis (TB), and many countries have adopted it into …